Efficacy and safety of microneedle injection of extracellular vesicles from mesenchymal stem cells in treatment of melasma
10.3760/cma.j.issn.1671-0290.2024.06.004
- VernacularTitle:间充质干细胞外泌体微针导入治疗黄褐斑的效果和安全性研究
- Author:
Liping YI
1
;
Yue MAI
;
Min YIN
;
Shanshan WU
;
Jiawei HE
;
Miaomiao LI
;
Lei YI
;
Shuaihua LI
;
Huan ZHOU
;
Peihui LI
;
Shan YIN
;
Qilei HE
;
Jia ZHOU
;
Changqing YAN
;
Xiang LIU
Author Information
1. 长沙美莱医疗美容医院皮肤科，长沙 410000
- Keywords:
Chloasma;
Treatment outcome;
Mesenchymal stem cell;
Exocrine body;
Microneedle
- From:
Chinese Journal of Medical Aesthetics and Cosmetology
2024;30(6):536-540
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect and safety of mesenchymal stem cell exosome microneedle introduction in the treatment of melasma.Methods:Thirty cases of female patients with stable melasma in the Department of Dermatology, Changsha Meilai Medical Beauty Hospital, aged (36±5) years and with a disease duration of (42.4±20.7) months, from July 2021 to July 2022, were retrospectively included. According to Fitzpatrick skin typing, 23 cases of type Ⅲ and 7 cases of type Ⅳ were included. All patients were locally anesthetized with lidocaine cream for 30 min, and rolled with a 0.5 mm needle in a zigzag pattern with even force, in the order of the right cheek, the left cheek, the forehead, the nose, the mandible, and the upper lip. During the rolling process, 3 ml of MSC exosome medical liquid wound dressing was applied to the facial skin, and after it was fully absorbed, exosome was locally readministered in the area of melasma. Treatment ended with a slight redness at the site of application. 1 MSC exosome wound dressing was appllied as a cold compress for 15 min after treatment. Treatment was given once every 2 weeks for 6 consecutive sessions. All the patients were followed up at 4 and 12 weeks after the last session, and the area and severity index of melasma (MASI) were scored before and after the treatment, the clinical efficiency and patient satisfaction rate and the incidence of adverse reactions were also counted.Results:At 4 and 12 weeks after the end of treatment, the skin color of all 30 patients was brighter than that before treatment, and no recurrence of melasma symptoms seen. At 12 weeks after the end of treatment, the decrease rate of MASI score was 66.1%, among which the decrease rate of MASI score in patients with type Ⅲ melasma was 63.9%, and the decrease rate of MASI score in patients with type Ⅳ melasma was 63.9%. Among the 30 patients, 1 case was cured, 25 cases showed obvious improved, 4 cases were improved, and no cases were ineffective, with an effective rate of 86.7% (26/30). Five patients were very satisfied, 18 patients were satisfied, 6 patients were generally satisfied, and 1 patient was dissatisfied; the patient satisfaction rate was 76.7% (23/30). No serious adverse reactions occurred in all patients.Conclusions:MSC exosome microneedle introduction is safe and effective in the treatment of melasma without serious adverse reactions.
